Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has today made the much awaited announcement. It disclosed that its exclusive license with Novartis AG (ADR) (NYSE:NVS) towards the commercialization of emricasan had become effective. The Collaboration and License Agreement which was signed by the two parties in December 2016 will go down records as a very transformative moment for the two business giants.
According to some top analysts, Emricasan has proved quite effective in the treatment of a wide range of liver complications. At the moment, experts are evaluating it in the four Phase 2b clinical trials as a potential cure for fibrosis and liver cirrhosis that emanate from hepatitis C virus (HCV) infection or nonalcoholic steatohepatitis (NASH).
While addressing a board meeting recently, one of the top executives working with Conatus said one thing that a lot of people don’t know. He outlined that the anticipated and secured funding provided under Novartis agreement had played a critical role towards helping them carry out successful business operations.
The current financial resources will as a matter of fact help the provider sustain the ongoing clinical development activities as well as maintain its operations according to Yahoo.
Steven J. Mento, a co-founder of Conatus has expressed that they were happy with the far they had come with Novartis in terms of business dealings. He expressed great optimism in the fact that they were going to achieve much in terms of achieving immense business success.
While speaking to a number of top news reporters he said, “We look forward to working together on emricasan’s development, both as a single agent for NASH cirrhosis and as a component of potential drug combinations for NASH fibrosis. In parallel, we are advancing toward a planned announcement later in 2017 of independent pipeline development opportunities aimed at building additional long-term value for our shareholders beyond emricasan.”
Most of the top health providers globally will agree to the fact that the technological advancements that have been sweeping across the globe have played an important role. They have helped towards the manufacture of top medical solutions that have served the needs of patients around the globe. The two giants are looking forward generate more revenues in years to come.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: